These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 21826000

  • 1. Denosumab: benefits of RANK ligand inhibition in cancer patients.
    Lipton A, Jacobs I.
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
    [Abstract] [Full Text] [Related]

  • 2. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.
    J Clin Oncol; 2011 Mar 20; 29(9):1125-32. PubMed ID: 21343556
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. New developments for treatment and prevention of bone metastases.
    Body JJ.
    Curr Opin Oncol; 2011 Jul 20; 23(4):338-42. PubMed ID: 21519257
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
    Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S.
    J Clin Oncol; 2009 Apr 01; 27(10):1564-71. PubMed ID: 19237632
    [Abstract] [Full Text] [Related]

  • 7. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.
    Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman RE, Paterson AH, Gao GM, Kinsey AC, Peterson MC, Jun S.
    Clin Cancer Res; 2008 Oct 15; 14(20):6690-6. PubMed ID: 18927312
    [Abstract] [Full Text] [Related]

  • 8. Denosumab for the management of bone disease in patients with solid tumors.
    Body JJ.
    Expert Rev Anticancer Ther; 2012 Mar 15; 12(3):307-22. PubMed ID: 22192269
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
    Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, Fallowfield L, Fujiwara Y, Jassem J, Paterson AH, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A.
    Clin Cancer Res; 2012 Sep 01; 18(17):4841-9. PubMed ID: 22893628
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
    Snedecor SJ, Carter JA, Kaura S, Botteman MF.
    Clin Ther; 2012 Jun 01; 34(6):1334-49. PubMed ID: 22578308
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [The clinical merit of anti-RANKL antibody denosumab in prostate cancer].
    Akaza H, Tsukamoto T, Suzuki K, Namiki M, Ozono S, Naitodept S.
    Gan To Kagaku Ryoho; 2012 Feb 01; 39(2):207-12. PubMed ID: 22333629
    [Abstract] [Full Text] [Related]

  • 18. RANKL inhibition in the treatment of bone metastases.
    Lipton A, Jun S.
    Curr Opin Support Palliat Care; 2008 Sep 01; 2(3):197-203. PubMed ID: 18685421
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW, Lambing CL, Kostenuik PJ, Grauer A.
    Clin Ther; 2012 Mar 01; 34(3):521-36. PubMed ID: 22440513
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.